Madrigal Pharmaceuticals is continuing to splash the cash this year on liver disease drugs it can combine with its own ...

Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why PFE stock is a strong buy.

Johnson & Johnson JNJ and Pfizer PFE rank among the world’s largest pharmaceutical companies, each with broad and diversified healthcare portfolios. J&J operates primarily through its pharmaceuticals ...

Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.

In lieu of a Super Bowl ad this year, Pfizer has unveiled a year-long cancer campaign that aims to encourage screening.

The deal on drug prices between the US Administration and Pfizer will leave the margins of innovative pharma companies intact. Yet, benefits to consumers will be modest. Furthermore, prices for ...

Historical patterns indicate that abrupt fluctuations in the market can impact any firm, regardless of its seeming dominance.

As 2025 results reveal a mixed year for Pfizer, the company is looking to turn its fortunes around with newly acquired Metsera's obesity assets.

To stir up support for the fight against cancer, Pfizer has turned to one of the most iconic pep talks of all time. | To stir ...

Add Yahoo as a preferred source to see more of our stories on Google. U.S. President Donald Trump shakes hands with Pfizer CEO Albert Bourla, on the day he announces a deal with Pfizer to sell drugs ...